Effectiveness and Safety of Rituximab in Patients with Refractory Juvenile Idiopathic Arthritis: A Tertiary Center Experience. (PubMed, Pharmaceuticals (Basel)) - Sep 27, 2026 - "Rituximab demonstrated an acceptable safety profile, with a total of 351 adverse events (non-serious AEs: 304/351, 87%) and a serious AE rate of 0.8 per 100 patient-years. Rituximab can reduce disease activity and lower the dose of oral glucocorticoids in patients with refractory JIA, serving as a viable therapeutic option with an acceptable safety profile."
Journal • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Pediatrics • Rheumatoid Arthritis • Rheumatology
|
|
Aleksandra M Chomakhidze; Anna N Fetisova; Christina V Chibisova; Dmitry A Kudlay; Ekaterina I Alexeeva; Elizaveta A Krekhova; Irina T Tsulukiya; Ivan A Kriulin; Kseniya B Isaeva; Maria S Botova; Maria Y Kokina; Meiri S Shingarova; Mikhail M Kostik; Natalia M Kondrateva; Tatiana Y Kriulina; Tatyana M Dvoryakovskaya
|